Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment ...

If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG, ...

For additional photos, logos and other branding elements, visit Brand.csl.com and Create an Account in the External Users Only box.

SUMMIT, N.J., September 18, 2023 -- CSL Seqirus, a business of CSL (ASX:CSL), today unveiled new analyses that underscore the potential of influenza vaccines in alleviating the burden of seasonal ...

Are you interested in receiving our latest news? Simply fill out the form below to receive news alerts directly to your inbox. To receive releases from a specific CSL business unit, select customize ...